Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

SARGRAMOSTIM for Malignant melanoma: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 24 adverse event reports in the FDA FAERS database where SARGRAMOSTIM was used for Malignant melanoma.

Most Reported Side Effects for SARGRAMOSTIM

Side Effect Reports % Deaths Hosp.
Off label use 98 16.5% 12 10
Pyrexia 76 12.8% 3 23
Pain 56 9.4% 2 1
Hospitalisation 31 5.2% 0 24
Death 30 5.1% 29 0
Hypotension 25 4.2% 3 18
Device related infection 23 3.9% 1 1
Cough 20 3.4% 1 4
Febrile neutropenia 20 3.4% 1 5
Disease progression 18 3.0% 9 1
Device related bacteraemia 17 2.9% 0 0
Fatigue 16 2.7% 1 8
Hypersensitivity 16 2.7% 0 4
Nausea 16 2.7% 3 2
Injection site erythema 14 2.4% 0 0

Other Indications for SARGRAMOSTIM

Neuroblastoma (88) Product used for unknown indication (48) Alveolar proteinosis (44) Pancreatic carcinoma (40) Pancreatic carcinoma metastatic (39) Neutropenia (35) Adrenal gland cancer (26) Prostate cancer (17) Neoplasm malignant (12) Bladder cancer (7)

Other Drugs Used for Malignant melanoma

NIVOLUMAB (10,599) IPILIMUMAB (8,903) DABRAFENIB (5,277) TRAMETINIB DIMETHYL SULFOXIDE (3,841) PEMBROLIZUMAB (3,261) BINIMETINIB (2,613) ENCORAFENIB (2,591) VEMURAFENIB (2,548) TRAMETINIB (1,448) COBIMETINIB (1,324)

Related Pages

SARGRAMOSTIM Full Profile All Malignant melanoma Drugs SARGRAMOSTIM Demographics SARGRAMOSTIM Timeline